Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Dermatitis

Subtypes of Dermatitis

Atopic Dermatitis 52 Toxic epidermal necrolysis 3 Allergic contact dermatitis 2 Hand-foot syndrome 1

60 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for dermatitis

12 trials tracked for dermatitis: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 14 citations.

12Trials tracked

6Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 3 6 Phase 2 2 Other / NA 4

Phase 3 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects Completed · 14 cited
Phase 3 A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis Completed · 9 cited
Phase 3 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Completed · 4 cited
Phase 3 Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Completed
Phase 3 A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis Completed
Phase 3 Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202) Completed

Show 6 more trials

Phase 2 Effect of Benralizumab in Atopic Dermatitis Completed
Phase 2 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis Completed
N/A Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam Completed
N/A Human Repeated Insult Patch Test Completed
N/A Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam Completed
N/A A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD) Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Dermatitis: what the trials found

Several systemic therapies demonstrate significant efficacy in managing dermatitis symptoms. PF-04965842 (100 mg) significantly extended the time to loss of response and the time to first loss of response based on IGA scores compared to other cohorts (p<0.0001) ¹. Additionally, PF-04965842 showed high rates of EASI-75 achievement at week 12 (up to 70.3%) and significant improvements in pruritus numerical rating scales (NRS) ³.

Lebrikizumab demonstrated statistically significant improvements in clinical outcomes by week 16, with a substantial percentage of patients achieving an IGA score of 0 or 1 and EASI-75 (p<0.001), alongside a significant reduction in mean EASI scores ².

Antihistamine treatments show varying results for pruritus management. Desloratadine (5 mg) significantly reduced pruritus/itch scores by week 2 (p<0.001) ⁵, while Levocetirizine did not show a statistically significant change in mean pruritus severity or duration over a 14-day period (p=0.4369, p=0.3549) ⁶. Bepotastine besilate was associated with improvements in pruritus scores and overall dermatitis severity at 2 weeks ⁴.

Recent results — preliminary, needs further review

Benralizumab was evaluated in a Phase 2 trial (N=20), but results are not yet corroborated.
Relizema ecofoam and DermoRelizema ecofoam showed improvements in EASI scores and pruritus-related VAS scores, but these findings are not yet corroborated.

For the clinician treating this condition

PF-04965842 (100 mg) is associated with prolonged durability of response and significant improvement in both EASI scores and pruritus severity [1, 3].
Lebrikizumab provides statistically significant improvements in EASI-75 and IGA scores by week 16 ².
Desloratadine (5 mg) is effective for rapid reduction of itch/pruritus scores within 2 weeks ⁵, whereas Levocetirizine did not show a statistically significant change in pruritus severity over 14 days ⁶.

AI synthesis of 6 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

‹ Prev 1 2 3 4 5 Next ›